Monopar Therapeutics (NASDAQ:MNPR) Price Target Raised to $40.00

Monopar Therapeutics (NASDAQ:MNPR) had its target price lifted by research analysts at HC Wainwright from $22.00 to $40.00 in a report issued on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s target price suggests a potential upside of 1.73% from the stock’s current price. HC Wainwright also issued estimates for Monopar Therapeutics’ FY2029 earnings at $3.66 EPS.

MNPR has been the topic of several other research reports. Rodman & Renshaw started coverage on Monopar Therapeutics in a research note on Friday, October 11th. They set a “buy” rating and a $50.00 price objective on the stock. Piper Sandler initiated coverage on Monopar Therapeutics in a report on Friday, January 10th. They set an “overweight” rating and a $72.00 price objective on the stock.

Monopar Therapeutics Trading Up 16.8 %

Monopar Therapeutics stock opened at $39.32 on Wednesday. The firm has a market capitalization of $239.85 million, a P/E ratio of -19.96 and a beta of 1.23. The business has a 50-day moving average of $23.76 and a 200-day moving average of $12.15. Monopar Therapeutics has a 1 year low of $1.54 and a 1 year high of $39.99.

Monopar Therapeutics (NASDAQ:MNPR) last issued its quarterly earnings data on Friday, November 8th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.09. Research analysts anticipate that Monopar Therapeutics will post -1.65 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO Karthik Radhakrishnan bought 1,550 shares of the business’s stock in a transaction on Monday, October 28th. The shares were purchased at an average price of $16.25 per share, for a total transaction of $25,187.50. Following the purchase, the chief financial officer now owns 1,550 shares of the company’s stock, valued at approximately $25,187.50. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 34.90% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.